라이엘 이뮤노파마(주)
US ˙ NasdaqGS ˙ US55083R1041

SecurityLYEL / Lyell Immunopharma, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series closes position in LYEL / Lyell Immunopharma, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 0 shares of Lyell Immunopharma, Inc. (US:LYEL) valued at $0 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 300,790 shares of Lyell Immunopharma, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Lyell Immunopharma EC US55083R1041 0 -300,790 -100.00 0 -100.00
2025-05-28 2025-03-31 NP Lyell Immunopharma EC US55083R1041 300,790 0 0.00 162 -16.15 0.0039
2025-02-25 2024-12-31 NP Lyell Immunopharma EC US55083R1041 300,790 0 0.00 193 -53.73 0.0042
2024-11-26 2024-09-30 NP Lyell Immunopharma EC US55083R1041 300,790 -33,604 -10.05 415 -14.26 0.0079
2024-08-26 2024-06-30 NP Lyell Immunopharma EC US55083R1041 334,394 24,264 7.82 485 -29.96 0.0099
2024-05-28 2024-03-31 NP Lyell Immunopharma EC US55083R1041 310,130 0 0.00 692 14.98 0.0144
2024-02-26 2023-12-31 NP Lyell Immunopharma EC US55083R1041 310,130 25,547 8.98 602 43.78 0.0128
2023-11-28 2023-09-30 NP Lyell Immunopharma EC US55083R1041 284,583 -22,552 -7.34 418 -57.17 0.0109
2023-08-25 2023-06-30 NP Lyell Immunopharma EC US55083R1041 307,135 35,987 13.27 977 52.74 0.0232
2023-05-26 2023-03-31 NP Lyell Immunopharma EC US55083R1041 271,148 0 0.00 640 -32.02 0.0170
2023-02-24 2022-12-31 NP Lyell Immunopharma EC US55083R1041 271,148 -1,803 -0.66 941 -53.00 0.0259
2022-11-25 2022-09-30 NP Lyell Immunopharma EC US55083R1041 272,951 5,651 2.11 2,001 14.81 0.0573
2022-08-25 2022-06-30 NP Lyell Immunopharma EC US55083R1041 267,300 98,687 58.53 1,743 104.70 0.0481
2022-05-26 2022-03-31 NP Lyell Immunopharma EC US55083R1041 168,613 132,856 371.55 851 208.33 0.0198
2022-02-25 2021-12-31 NP Lyell Immunopharma EC US55083R1041 35,757 0 0.00 277 -47.83 0.0060
2021-11-24 2021-09-30 NP Lyell Immunopharma EC US55083R1041 35,757 35,757 529 0.0117
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.